As part of this bimonthly processing,
ScienceWatch.com selects the Research Fronts with the largest absolute
increase in size in each of the 22 major
fields covered by
Essential Science IndicatorsSM
from Thomson
Reuters. The size of a research front is determined by the number of
core papers it contains. This Research Front on METASTATIC COLORECTAL CANCER from the field of
Clinical Medicine was
selected for mapping from the list of Top Topics for June 2008
(data from the first bimonthly period of 2008). The map is a diagrammatic
representation of the 26 core papers comprising the front
Clinical Medicine.
Each circle
represents a highly cited paper whose bibliographic information is displayed
when the user clicks on the circle. The lines between circles represent the
strongest co-citation links for each paper (that is, indicating that the papers
are frequently cited together). Papers close to each other on the map are
generally more highly co-cited. The most recent paper(s) are indicated in pink.
Core Papers
Label: Hurwitz-2004 Title: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer Journal: N ENGL J MED, 350 (23): 2335-2342 JUN 3 2004 Citations: 1442 Authors: Hurwitz, H;Fehrenbacher, L;Novotny, W;Cartwright, T;Hainsworth, J;Heim, W;Berlin, J;Baron, A;Griffing, S;Holmgren, E;Ferrara, N;Fyfe, G;Rogers, B;Ross, R;Kabbinavar, F Addresses:
Duke Univ, Med Ctr, Dept Med Oncol & Transplantat, Rm 3802,Red Zone,Duke S Clin,Box 3052, Durham, NC 27710 USA
Duke Univ, Med Ctr, Dept Med Oncol & Transplantat, Durham, NC 27710 USA
Kaiser Permanente, Vallejo, CA USA
Genentech Inc, San Francisco, CA 94080 USA
Ocala Oncol, Ocala, FL USA
Sarah Cannon Canc Ctr, Nashville, TN USA
Hematol & Oncol Associates NE Penn, Scranton, PA USA
Vanderbilt Univ, Nashville, TN USA
Calif Pacific Med Ctr, San Francisco, CA USA
Univ Calif Los Angeles, Los Angeles, CA USA
Label: Goldberg-2004 Title: A Randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer Journal: J CLIN ONCOL, 22 (1): 23-30 JAN 1 2004 Citations: 489 Authors: Goldberg, RM;Sargent, DJ;Morton, RF;Fuchs, CS;Ramanathan, RK;Williamson, SK;Findlay, BP;Pitot, HC;Alberts, SR Addresses:
Univ N Carolina, Div Hematol Oncol, N Cent Canc Treatment Grp, CB 7305,3009 Old Clin Bldg, Chapel Hill, NC 27599 USA
Univ N Carolina, Div Hematol Oncol, N Cent Canc Treatment Grp, Chapel Hill, NC 27599 USA
Univ N Carolina, Div Med Oncol, Chapel Hill, NC USA
Mayo Clin, Div Biostat, N Cent Canc Treatment Grp, Rochester, MN USA
Iowa Oncol Res Assoc, Community Clin Oncol Program, N Cent Canc Treatment Grp, Des Moines, IA USA
Dana Farber Canc Inst, Dept Oncol, Canc & Acute Leukemia Grp B, Boston, MA 02115 USA
Univ Pittsburgh, Inst Canc, Div Med Oncol, Eastern Cooperat Oncol Grp, Pittsburgh, PA USA
Univ Kansas, Med Ctr, Div Hematol & Oncol, SW Oncol Grp, Kansas City, KS 66103 USA
Natl Canc Inst Canada, St Catharines, ON, Canada
Label: Kabbinavar-2003 Title: Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU) leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer Journal: J CLIN ONCOL, 21 (1): 60-65 JAN 1 2003 Citations: 478 Authors: Kabbinavar, F;Hurwitz, HI;Fehrenbacher, L;Meropol, NJ;Novotny, WF;Lieberman, G;Griffing, S;Bergsland, E Addresses:
Univ Calif Los Angeles, Sch Med, Div Hematol Oncol, 10945 Le Conte Ave,Ste 2338J, Los Angeles, CA 90095 USA
Univ Calif Los Angeles, Sch Med, Div Hematol Oncol, Los Angeles, CA 90095 USA
Kaiser Permanente, Hematol Oncol Clin, Vallejo, CA USA
Genentech Inc, San Francisco, CA 94080 USA
Univ Calif San Francisco, Div Hematol Oncol, San Francisco, CA 94143 USA
Duke Univ, Div Hematol & Oncol, Durham, NC USA
Fox Chase Canc Ctr, Div Med Sci, Philadelphia, PA 19111 USA
Fox Chase Canc Ctr, Dept Populat Sci, Philadelphia, PA 19111 USA
Label: Saltz-2004 Title: Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor Journal: J CLIN ONCOL, 22 (7): 1201-1208 APR 1 2004 Citations: 438 Authors: Saltz, LB;Meropol, NJ;Loehrer, PJ;Needle, MN;Kopit, J;Mayer, RJ Addresses:
Mem Sloan Kettering Canc Ctr, Gastrointestinal Oncol Serv, Dept Med, 1275 York Ave, New York, NY 10021 USA
Mem Sloan Kettering Canc Ctr, Gastrointestinal Oncol Serv, Dept Med, New York, NY 10021 USA
Fox Chase Canc Ctr, Dept Med Oncol, Philadelphia, PA 19111 USA
Indiana Univ, Ctr Canc, Indianapolis, IN USA
Walther Canc Inst, Indianapolis, IN USA
Imclone Syst Inc, Somerville, NJ USA
Bristol Myers Squibb Inc, Wallingford, CT USA
Dana Farber Canc Inst, Dept Med Oncol, Boston, MA USA
Label: Tournigand-2004 Title: FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: A randomized GERCOR study Journal: J CLIN ONCOL, 22 (2): 229-237 JAN 15 2004 Citations: 438 Authors: Tournigand, C;Andre, T;Achille, E;Lledo, G;Flesh, M;Mery-Mignard, D;Quinaux, E;Couteau, C;Buyse, M;Ganem, G;Landi, B;Colin, P;Louvet, C;de Gramont, A Addresses:
Hop St Antoine, 184 Rue Faubourg, F-75571 Paris 12, France
Hop St Antoine, F-75571 Paris 12, France
GERCOR, Paris, France
Hop Tenon, F-75970 Paris, France
Hop Georges Pompidou, Paris, France
Aventis, Paris, France
Int Inst Drug Dev, Paris, France
Clin Orangerie, Strasbourg, France
Clin St Jean, Lyon, France
Clin Drevon, Dijon, France
Ctr Jean Bernard, Le Mans, France
Clin Courlancy, Reims, France
Int Inst Drug Dev, Brussels, Belgium
Label: Willett-2004 Title: Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer Journal: NATURE MED, 10 (2): 145-147 FEB 2004 Citations: 409 Authors: Willett, CG;Boucher, Y;di Tomaso, E;Duda, DG;Munn, LL;Tong, RT;Chung, DC;Sahani, DV;Kalva, SP;Kozin, SV;Mino, M;Cohen, KS;Scadden, DT;Hartford, AC;Fischman, AJ;Clark, JW;Ryan, DP;Zhu, AX;Blaszkowsky, LS;Chen, HX;Shellito, PC;Lauwers, GY;Jain, RK Addresses:
Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA
Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA
Massachusetts Gen Hosp, Div Gastroenterol, Boston, MA 02114 USA
Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA
Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA
Massachusetts Gen Hosp, AIDS Res Ctr Expt Hematol, Boston, MA 02114 USA
Massachusetts Gen Hosp, Dept Nucl Med, Boston, MA 02114 USA
Massachusetts Gen Hosp, Div Hematol Oncol, Boston, MA 02114 USA
Massachusetts Gen Hosp, Dept Surg, Boston, MA 02114 USA
Harvard Univ, Sch Med, Boston, MA 02114 USA
NCI, Canc Therapy Evaluat Program, Rockville, MD 20852 USA
Label: Chung-2005 Title: Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry Journal: J CLIN ONCOL, 23 (9): 1803-1810 MAR 20 2005 Citations: 208 Authors: Chung, KY;Shia, J;Kemeny, NE;Shah, M;Schwartz, GK;Tse, A;Hamilton, A;Pan, D;Schrag, D;Schwartz, L;Klimstra, DS;Fridman, D;Kelsen, DP;Saltz, LB Addresses:
Mem Sloan Kettering Canc Ctr, Gastrointestinal Oncol Serv, H-816, New York, NY 10021 USA
Mem Sloan Kettering Canc Ctr, Gastrointestinal Oncol Serv, New York, NY 10021 USA
Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY 10021 USA
Mem Sloan Kettering Canc Ctr, Dept Pathol, New York, NY 10021 USA
Mem Sloan Kettering Canc Ctr, Dept Diagnost Imaging, New York, NY 10021 USA
Label: Rothenberg-2003 Title: Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: Interim results of a phase III trial Journal: J CLIN ONCOL, 21 (11): 2059-2069 JUN 1 2003 Citations: 197 Authors: Rothenberg, ML;Oza, AM;Bigelow, RH;Berlin, JD;Marshall, JL;Ramanathan, RK;Hart, LL;Gupta, S;Garay, CA;Burger, BG;Le Bail, N;Haller, DG Addresses:
Vanderbilt Ingram Canc Ctr, 777 Preston Res Bldg, Nashville, TN 37232 USA
Vanderbilt Ingram Canc Ctr, Nashville, TN 37232 USA
Princess Margaret Hosp, Toronto, ON M4X 1K9, Canada
Sanofi Synthelabo Res, Malvern, Worcs, England
Univ Pittsburgh, Inst Canc, Pittsburgh, PA 15260 USA
Univ Penn, Ctr Canc, Philadelphia, PA 19104 USA
Lombardi Canc Ctr, Washington, DC USA
Florida Canc Specialists, Ft Myers, FL USA
Label: Grothey-2004 Title: Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment Journal: J CLIN ONCOL, 22 (7): 1209-1214 APR 1 2004 Citations: 173 Authors: Grothey, A;Sargent, D;Goldberg, RM;Schmoll, HJ Addresses:
Mayo Clin, Div Med Oncol, 200 1st St SW, Rochester, MN 55905 USA
Mayo Clin, Div Med Oncol, Rochester, MN 55905 USA
Mayo Clin, Div Biostat, Rochester, MN 55905 USA
Univ N Carolina, Div Oncol, Chapel Hill, NC USA
Univ Halle, Dept Hematol & Oncol, Halle Saale, Germany
Label: Prewett-2002 Title: Enhanced antitumor activity of anti-epidermal growth factor receptor monoclonal antibody IMC-C225 in combination with irinotecan (CPT-11) against human colorectal tumor xenografts Journal: CLIN CANCER RES, 8 (5): 994-1003 MAY 2002 Citations: 145 Authors: Prewett, MC;Hooper, AT;Bassi, R;Ellis, LM;Waksal, HW;Hicklin, DJ Addresses:
ImClone Syst Inc, Dept Immunol, 180 Varick St, New York, NY 10014 USA
ImClone Syst Inc, Dept Immunol, New York, NY 10014 USA
Univ Texas, MD Anderson Canc Ctr, Dept Surg Oncol, Houston, TX 77030 USA
Label: Kabbinavar-2005 Title: Addition of bevacizurnab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: Results of a randomized phase II trial Journal: J CLIN ONCOL, 23 (16): 3697-3705 JUN 1 2005 Citations: 135 Authors: Kabbinavar, FF;Schulz, J;McCleod, M;Patel, T;Hamm, JT;Hecht, JR;Mass, R;Perrou, B;Nelson, B;Novotny, WF Addresses:
Univ Calif Los Angeles, Sch Med, Div Hematol Oncol, 10945 LeConte Ave,Suite 2338J, Los Angeles, CA 90095 USA
Univ Calif Los Angeles, Sch Med, Div Hematol Oncol, Los Angeles, CA 90095 USA
Genentech Inc, San Francisco, CA 94080 USA
Virginia Oncol Associates, Newport News, VA USA
Florida Canc Specialists, Ft Myers, FL USA
Mid Ohio Oncol Hematol Inc, Westerville, OH USA
Louisville Oncol, Louisville, KY USA
Label: Hurwitz-2005 Title: Bevacizurnab in combination with fluorouracil and leucovorin: An active regimen for first-line metastatic colorectal cancer Journal: J CLIN ONCOL, 23 (15): 3502-3508 MAY 20 2005 Citations: 108 Authors: Hurwitz, HI;Fehrenbacher, L;Hainsworth, JD;Heim, W;Berlin, J;Holmgren, E;Hambleton, J;Novotny, WF;Kabbinavar, F Addresses:
Duke Univ, Med Ctr, Dept Med Oncol & Transplantat, Room 25132,Morris Bldg,Box 3052, Durham, NC 27710 USA
Duke Univ, Med Ctr, Dept Med Oncol & Transplantat, Durham, NC 27710 USA
Genentech Inc, San Francisco, CA 94080 USA
Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90024 USA
Sarah Cannon Canc Ctr, Nashville, TN USA
Hematol & Canc Ctr NE Penn, Dunmore, PA USA
Vanderbilt Univ, Med Ctr, Div Med Oncol, Nashville, TN USA
Label: Kabbinavar-2005 Title: Combined analysis of efficacy: The addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer Journal: J CLIN ONCOL, 23 (16): 3706-3712 JUN 1 2005 Citations: 87 Authors: Kabbinavar, FF;Hambleton, J;Mass, RD;Hurwitz, HL;Bergsland, E;Sarkar, S Addresses:
Genentech Inc, Med Affairs, 1 DNA Way, San Francisco, CA 94080 USA
Genentech Inc, Med Affairs, San Francisco, CA 94080 USA
Univ Calif Los Angeles, Los Angeles, CA 90024 USA
Univ Calif San Francisco, San Francisco, CA 94143 USA
Duke Univ, Durham, NC 27706 USA
Label: Lievre-2006 Title: KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer Journal: CANCER RES, 66 (8): 3992-3995 APR 15 2006 Citations: 70 Authors: Lievre, A;Bachet, JB;Le Corre, D;Boige, V;Landi, B;Emile, JF;Cote, JF;Tomasic, G;Penna, C;Ducreux, M;Rougier, P;Penault-Llorca, F;Laurent-Puig, P Addresses:
Univ Paris Descartes, INSERM, UMR 775, 45 Rue St Peres, F-75006 Paris, France
Univ Paris Descartes, INSERM, UMR 775, F-75006 Paris, France
Hop Europeen Georges Pompidou, Assistance Publ Hop Paris, Paris, France
Hop Ambroise Pare, Assistance Publ Hop Paris, Boulogne Billancourt, France
Univ Versailles, F-78000 Versailles, France
Inst Gustave Roussy, Villejuif, France
Ctr Jean Perrin, Clermont Ferrand, France
Univ Auvergne, Clermont Ferrand, France
Label: Colucci-2005 Title: Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: A Multicenter study of the Gruppo Oncologico Dell'Italia Meridionale Journal: J CLIN ONCOL, 23 (22): 4866-4875 AUG 1 2005 Citations: 63 Authors: Colucci, G;Gebbia, V;Paoletti, G;Giuliani, F;Caruso, M;Gebbia, N;Carteni, G;Agostara, B;Pezzella, G;Manzione, L;Borsellino, N;Misino, A;Romito, S;Durini, E;Cordio, S;Di Seri, M;Lopez, M;Maiello, E Addresses:
Inst Oncol, Med & Expt Oncol Unit, Via Amendola 209, I-70126 Bari, Italy
Inst Oncol, Med & Expt Oncol Unit, I-70126 Bari, Italy
Univ Palermo, Palermo, Italy
Maddalena Hosp, Palermo, Italy
M Ascoli Hosp, Palermo, Italy
Ist Regina Elena, I-00161 Rome, Italy
Univ Roma La Sapienza, Rome, Italy
S Luigi Hosp, Ctr Oncol, Catania, Italy
Cardarelli Hosp, Naples, Italy
Osped Nord, Taranto, Italy
San Carlo Hosp, Potenza, Italy
Cardarelli Hosp, Campobasso, Italy
G Panico Hosp, Tricase, Italy
Label: Lenz-2006 Title: Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines Journal: J CLIN ONCOL, 24 (30): 4914-4921 OCT 20 2006 Citations: 34 Authors: Lenz, HJ;Van Cutsem, E;Khambata-Ford, S;Mayer, RJ;Gold, P;Stella, P;Mirtsching, B;Cohn, AL;Pippas, AW;Azarnia, N;Tsuchihashi, Z;Mauro, DJ;Rowinsky, EK Addresses:
Imclone Syst, 33 Imclone Dr, Branchburg, NJ 08876 USA
Univ So Calif, Norris Comprehens Canc Ctr, Los Angeles, CA USA
Univ Hosp Gasthuisberg, B-3000 Louvain, Belgium
Bristol Myers Squibb Co, Pharmaceut Res Inst, Princeton, NJ 08543 USA
Dana Farber Partners Canc Care, Boston, MA USA
Swedish Canc Inst, Seattle, WA USA
St Joseph Mercy Hosp, Ann Arbor, MI 48104 USA
Ctr Oncol Res & Treatment, Dallas, TX USA
Rocky Mt Canc Ctr, Denver, CO USA
Lakeland Reg Canc Ctr, Lakeland, FL USA
Imclone Syst Inc, New York, NY USA
Label: Giantonio-2007 Title: Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: Results from the Eastern Cooperative Oncology Group Study E3200 Journal: J CLIN ONCOL, 25 (12): 1539-1544 APR 20 2007 Citations: 29 Authors: Giantonio, BJ;Catalano, PJ;Meropol, NJ;O'Dwyer, PJ;Mitchell, EP;Alberts, SR;Schwartz, MA;Benson, AB Addresses:
12 Penn Tower,3400 Spruce St, Philadelphia, PA 19104 USA
Univ Penn, Philadelphia, PA 19104 USA
Fox Chase Canc Ctr, Philadelphia, PA 19111 USA
Thomas Jefferson Univ, Philadelphia, PA 19107 USA
Dana Farber Canc Inst, Boston, MA 02115 USA
Mayo Clin, Rochester, MN USA
Mt Sinai Med Ctr, Miami, FL USA
Northwestern Univ, Chicago, IL 60611 USA
Label: Khambata-Ford-2007 Title: Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab Journal: J CLIN ONCOL, 25 (22): 3230-3237 AUG 1 2007 Citations: 12 Authors: Khambata-Ford, S;Garrett, CR;Meropol, NJ;Basik, M;Harbison, CT;Wu, S;Wong, TW;Huang, X;Takimoto, CH;Godwin, AK;Tan, BR;Krishnamurthi, SS;Burris, HA;Poplin, EA;Hidalgo, M;Baselga, J;Clark, EA;Mauro, DJ Addresses:
Bristol Myers Squibb Co, Pharmaceut Res Inst, 311 Pennington Rocky Hill Rd 3B-2 06, Princeton, NJ 08543 USA
Bristol Myers Squibb Co, Pharmaceut Res Inst, Princeton, NJ 08543 USA
Canc Inst New Jersey, New Brunswick, NJ USA
H Lee Moffitt Canc Ctr & Res Inst, Div Gastrointestinal Oncol, Tampa, FL USA
Fox Chase Canc Ctr, Div Med Sci & Populat Sci, Philadelphia, PA 19111 USA
Canc Therapy & Res Ctr S Texas, Inst Drug Dev, San Antonio, TX 78229 USA
Washington Univ, Sch Med, St Louis, MO USA
Univ Hosp Cleveland, Case Comprehens Canc Ctr, Cleveland, OH 44106 USA
Case Western Reserve Univ, Cleveland, OH 44106 USA
Sarah Cannon Canc Ctr, Nashville, TN USA
Sidney Kimmel Comprehens Canc Ctr Johns Hop, Baltimore, MD USA
McGill Univ, Sir Mortimer B Davis Jewish Hosp, Quebec City, PQ, Canada
Univ Autonoma Barcelona, Vall Dhebron Univ Hosp, Oncol Program & Med Oncol Ser, E-08193 Barcelona, Spain